These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 26415374)

  • 21. The prognostic utility and the association of serum light chains (free and total) and absolute lymphocyte count in patients with newly diagnosed diffuse large B-cell lymphoma.
    Han X; Wang J; Zhang N; Yao J; Feng Y; Li D; Liu P; Yang J; Zhou S; Qin Y; Yang S; Gui L; He X; Shi Y
    Leuk Res; 2014 Nov; 38(11):1291-8. PubMed ID: 25287608
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens.
    Tacchetti P; Cavo M; Rocchi S; Pezzi A; Pantani L; Brioli A; Testoni N; Terragna C; Zannetti BA; Mancuso K; Marzocchi G; Borsi E; Martello M; Rizzello I; Zamagni E
    Leuk Lymphoma; 2016 Sep; 57(9):2058-64. PubMed ID: 26763357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma.
    Iwama K; Chihara D; Tsuda K; Ugai T; Sugihara H; Nishida Y; Yamakura M; Takeuchi M; Matsue K
    Eur J Haematol; 2013 Feb; 90(2):134-41. PubMed ID: 23210517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple myeloma can be accurately diagnosed in acute kidney injury patients using a rapid serum free light chain test.
    Heaney JLJ; Campbell JP; Yadav P; Griffin AE; Shemar M; Pinney JH; Drayson MT
    BMC Nephrol; 2017 Jul; 18(1):247. PubMed ID: 28728609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Test of Serum Free Light Chain and Its Clinical Significance in Light Chain Multiple Myeloma].
    Song P; An ZM; Zhou XG; Li F; Wang LP; Zhao Q; Yu YP; Zhai YP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1357-61. PubMed ID: 26524037
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system.
    Snozek CL; Katzmann JA; Kyle RA; Dispenzieri A; Larson DR; Therneau TM; Melton LJ; Kumar S; Greipp PR; Clark RJ; Rajkumar SV
    Leukemia; 2008 Oct; 22(10):1933-7. PubMed ID: 18596742
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.
    Hutchison CA; Plant T; Drayson M; Cockwell P; Kountouri M; Basnayake K; Harding S; Bradwell AR; Mead G
    BMC Nephrol; 2008 Sep; 9():11. PubMed ID: 18808676
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The roles of serum free light chain ratio in the diagnosis and prognosis of newly diagnosed multiple myeloma].
    Wang PF; Xu Y; Yan S; Yao Y; Zheng HF; Ma L; Jin S; Xu Y; Gong FR; Zhou JZ; Chang HR; Fu CC
    Zhonghua Xue Ye Xue Za Zhi; 2016 May; 37(5):377-82. PubMed ID: 27210871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Serum free light chains for diagnosis and follow-up of multiple myeloma].
    Jung S; Kim M; Lim J; Kim Y; Han K; Min CK; Min WS
    Korean J Lab Med; 2008 Jun; 28(3):169-73. PubMed ID: 18594166
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma.
    Dejoie T; Corre J; Caillon H; Hulin C; Perrot A; Caillot D; Boyle E; Chretien ML; Fontan J; Belhadj K; Brechignac S; Decaux O; Voillat L; Rodon P; Fitoussi O; Araujo C; Benboubker L; Fontan C; Tiab M; Godmer P; Luycx O; Allangba O; Pignon JM; Fuzibet JG; Legros L; Stoppa AM; Dib M; Pegourie B; Orsini-Piocelle F; Karlin L; Arnulf B; Roussel M; Garderet L; Mohty M; Meuleman N; Doyen C; Lenain P; Macro M; Leleu X; Facon T; Moreau P; Attal M; Avet-Loiseau H
    Blood; 2016 Dec; 128(25):2941-2948. PubMed ID: 27729323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum free light chains and oligoclonal bands in patients with multiple myeloma and autologous stem cell transplantation.
    Alejandre ME; Pavlovsky MA; Remaggi G; Corrado C; Fernandez I; Milone G; Pavlovsky A; Madalena L; Pandolfo M; Facio ML; Bresciani P; Pavlovsky S; Pizzolato MA
    Clin Chem Lab Med; 2012 Apr; 50(6):1093-7. PubMed ID: 22706252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum free light chains: diagnostic and prognostic value in multiple myeloma.
    Sthaneshwar P; Nadarajan V; Maniam JA; Nordin N; Gin Gin G
    Clin Chem Lab Med; 2009; 47(9):1101-7. PubMed ID: 19728852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of response and progression in multiple myeloma with serum free light chains assay: corroboration of the serum free light chain response definitions.
    Khoriaty R; Hussein MA; Faiman B; Kelly M; Kalaycio M; Baz R
    Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):E10-3. PubMed ID: 20223721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum free light chains in clinical laboratory diagnostics.
    Jenner E
    Clin Chim Acta; 2014 Jan; 427():15-20. PubMed ID: 23999048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing the efficiency of free light chain assay in monitoring patients with multiple myeloma before and after autologous stem cell transplantation along with serum protein electrophoresis and serum protein immunofixation.
    Dogaru M; Lazăr V; Coriu D
    Roum Arch Microbiol Immunol; 2011; 70(1):15-22. PubMed ID: 21717807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Using Both Lactic Dehydrogenase Levels and the Ratio of Involved to Uninvolved Free Light Chain Levels as Risk Factors Improves Risk Assessment in Patients With Newly Diagnosed Multiple Myeloma.
    Guo Z; Li H; Geng Y; Cui J; Tang N; Li D
    Am J Med Sci; 2018 Apr; 355(4):350-356. PubMed ID: 29661348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The correlation of serum immunoglobulin free light chain levels and selected biological markers in multiple myeloma.
    Pika T; Minarik J; Schneiderka P; Budikova M; Langova K; Lochman P; Bacovsky J; Farbiakova V; Scudla V
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2008 Jun; 152(1):61-4. PubMed ID: 18795076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urine immunofixation electrophoresis and serum free light chain analyses benefit diagnosis of multiple myeloma in orthopedic patients with normal serum total proteins, creatinine, calcium, and hemoglobin.
    Jia Z; Xia J; Lu Q
    Lab Med; 2024 Jul; 55(4):454-459. PubMed ID: 38141202
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR.
    Hansen CT; Pedersen PT; Nielsen LC; Abildgaard N
    Eur J Haematol; 2014 Nov; 93(5):407-13. PubMed ID: 24809596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Assessment of serum free light chain of patients with multiple myeloma and clinical significance thereof].
    Sui WW; Yao HJ; Wang YF; Wang L; Zhang K; Xu Y; Qiu LG
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(44):3158-60. PubMed ID: 18269880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.